By Eduardo Bacci — The Investigative Journal
The SEC’s EDGAR pipeline delivered another dense 24 hours of corporate disclosure and enforcement activity, with executive transitions, merger agreements, and a newly settled insider trading matter all landing in the public record. This edition of SEC Watch surveys eight notable filings and proceedings drawn from EDGAR, SEC press releases, and litigation releases. Each entry summarizes what the record shows, flags the significance for investors and accountability watchers, and — where warranted — notes angles The Investigative Journal intends to pursue in follow-up reporting.
1. Conagra Brands (NYSE: CAG) — CEO succession triggers Item 5.02
Filings indicate that on April 13, 2026, Conagra Brands disclosed on Form 8-K under Item 5.02 that its board had determined Sean Connolly will cease to serve as president and chief executive officer effective May 31, 2026. The company’s board approved the appointment of John Brase as president and CEO effective on his first day of employment, expected June 1, 2026, according to the filing. Mr. Connolly is also ending his service on the Conagra board as of the same effective date.
Records further suggest that Mr. Connolly will be eligible to receive separation benefits under his pre-existing Letter of Agreement, consistent with a termination “without Cause.” Receipt of those benefits is contingent on execution of a customary release of claims in favor of the company. Successions at consumer staples issuers — particularly those occurring outside a proxy-season window — often attract attention under Item 5.02 disclosure rules because the company must specify the reasons for the departure and any compensatory arrangements.
For TIJ readers, the significance is twofold. First, Conagra has been navigating a prolonged period of margin pressure in its frozen and refrigerated portfolios; a CEO handoff at this stage can precipitate strategic review, restructuring charges, or divestitures, each of which would generate additional 8-K activity. Second, the compensatory arrangements disclosed in the 8-K — and any subsequent DEF 14A commentary — will help establish whether pay is being aligned with performance in the manner shareholder advisory firms have been demanding.
Filing: Conagra Brands 8-K filings via SEC EDGAR.
2. Assertio Holdings (NASDAQ: ASRT) — $18 cash plus CVR take-private agreement
According to EDGAR filings, on April 8, 2026, Assertio Holdings, Inc. entered into an Agreement and Plan of Merger with Garda Therapeutics, Inc. and Audi Merger Sub, Inc. The agreement, disclosed on Form 8-K, provides for acquisition of Assertio through a cash tender offer of $18.00 per share, plus one contingent value right per share tied to future product milestones. The filing indicates a customary go-shop period and break-fee structure that observers of specialty-pharma M&A will want to scrutinize.
Specialty pharmaceutical deals of this size are often structured with CVRs to bridge valuation gaps between acquirer and target boards, particularly where revenue concentration or patent-cliff risk is meaningful. Data shows Assertio’s revenue base has historically been concentrated in a handful of branded products, which makes CVR design — and the disclosure of its milestones — a focal point for fairness-opinion analysis.
Investors evaluating the deal should watch the forthcoming Schedule 14D-9 and the preliminary proxy, which will contain the board’s financial advisor analysis, projections, and a detailed description of management retention arrangements. Pending litigation, if any, must be disclosed as it is filed.
Filing: Assertio Holdings 8-K filings via SEC EDGAR.
3. UL Solutions (NYSE: ULS) — €575M carve-out of Eurofins E&E unit
UL Solutions disclosed on Form 8-K that it had entered into a definitive agreement to acquire the electrical and electronics testing business of Eurofins Scientific for approximately €575 million. According to the filing, UL Solutions expects the transaction to add roughly $200 million of 2026 revenue and 44 laboratories, with a targeted closing in the fourth quarter of 2026, subject to regulatory approvals in multiple jurisdictions.
Cross-border carve-outs of this size raise antitrust questions in the EU, the UK, and — depending on customer mix — China. The 8-K does not, of course, adjudicate those questions; it merely identifies them as conditions precedent. Filings indicate UL Solutions intends to finance the transaction with a combination of cash and incremental term debt, which may be specified more precisely in a subsequent credit-agreement exhibit.
For accountability watchers, the disclosure is notable because UL Solutions has previously framed itself as an acquirer of bolt-on assets rather than integrator of a peer-scale carve-out. How management communicates integration risk in its next 10-Q — and in any Regulation FD-triggering investor calls — will be a barometer of execution confidence.
Filing: UL Solutions 8-K filings via SEC EDGAR.
4. BiomX Inc. (NYSE American: PHGE) — Accelerated option on Israeli defense engineering firm
On April 13, 2026, BiomX Inc. disclosed on Form 8-K that it had accelerated the exercise of a previously announced exclusive option and entered into a definitive agreement to acquire a controlling interest in DFSL, described in the filing as an Israeli defense engineering company. The filing indicates a $3 million promissory note was issued in connection with the transaction.
BiomX is historically a clinical-stage biotechnology company focused on bacteriophage therapy; its pivot toward a controlling stake in a defense engineering entity is unusual enough to warrant heightened scrutiny of the disclosure. Public records suggest investors will want to understand how the acquired entity is valued, how the new business segment will be reported for GAAP purposes, and whether any related-party considerations are present. Pending diligence, readers should treat the strategic rationale as unresolved.
Filing: BiomX Inc. 8-K filings via SEC EDGAR.
5. Ovintiv (NYSE: OVV) — $3B Anadarko asset sale, debt paydown
Ovintiv disclosed on Form 8-K that it had entered into an agreement to sell its Anadarko basin assets for approximately $3 billion, with proceeds earmarked primarily for debt reduction. According to the filing, the divestiture is consistent with previously articulated portfolio-concentration priorities focused on the Permian and Montney basins.
For energy-sector accountability, the significance lies in how the company will report capital returns to shareholders versus deleveraging, a balance that has been a central debate among upstream producers throughout the current commodity cycle. Data shows energy M&A has been elevated in 2026, and each 8-K of this size feeds into the aggregate picture regulators and the Department of Justice use to evaluate market concentration.
Filing: Ovintiv Inc. 8-K filings via SEC EDGAR.
6. Paramount Skydance (NASDAQ: PSKY) — Equity syndication for WBD merger
Paramount Skydance Corp. disclosed on Form 8-K details of the equity syndication and warrant structure underpinning its pending acquisition of Warner Bros. Discovery, Inc., which the parties publicly described in a February 27, 2026 merger agreement providing for $31 per share in cash, plus, if applicable, a ticking fee. The updated 8-K filings flesh out the financing stack that will enable the transaction to close.
Media-industry accountability reporters will want to parse both the governance side letters and the FCC transfer-of-control considerations, which typically surface in subsequent proxy materials and Schedule 14A filings. According to the record, no closing date has been finalized, and the transaction remains subject to regulatory review.
Filing: Paramount Skydance 8-K filings via SEC EDGAR.
7. SEC Enforcement — Jorgensen / Doximity settled insider trading charges
SEC litigation records show that on March 16, 2026, the Commission filed settled insider trading charges against Paul W. Jorgensen, the former chief revenue officer of Doximity, Inc. According to the SEC’s complaint, in August 2022 Mr. Jorgensen sold 61,162 shares of Doximity stock ahead of a quarterly earnings announcement based on material nonpublic information concerning lower-than-expected sales. The complaint further alleges that, days after his termination, Mr. Jorgensen again traded Doximity securities based on material nonpublic information regarding sales underperformance and a planned reduction in force.
Mr. Jorgensen consented to entry of a judgment, subject to court approval, in which he agreed to be permanently enjoined from future violations of the charged provisions and permanently barred from serving as an officer or director of a public reporting company. Under the bifurcated settlement, disgorgement, prejudgment interest, and any civil penalty will be determined by the court upon motion by the Commission. In a parallel criminal action, records indicate Mr. Jorgensen pled guilty to securities fraud in the Southern District of New York on January 9, 2026. Under established reporting principles, the civil matter is resolved as to liability only with respect to the consented-to injunction; the monetary component remains pending.
Litigation release: SEC Litigation Releases index.
8. SEC Press Release 2026-34 — FY2025 enforcement results and priorities shift
The SEC’s April 7, 2026 press release announced FY2025 enforcement results: 456 enforcement actions filed, including 303 standalone actions and 69 follow-on administrative proceedings, with orders for monetary relief totaling $17.9 billion, according to the Commission. The release frames the year as a recalibration under Chairman Paul Atkins, with a deliberate step back from what the Commission characterizes as “regulation by enforcement” and a renewed emphasis on fraud, investor harm, and congressional intent.
Filings indicate the Commission’s near-term priorities include offering frauds, market manipulation, insider trading, issuer disclosure violations, and breaches of fiduciary duty by investment advisers. Records suggest a parallel refresh of the Division of Enforcement manual is under way, as disclosed in press release 2026-20.
Press release: SEC Announces Enforcement Results for Fiscal Year 2025. Related: Division of Enforcement Updates to Enforcement Manual.
Filings that may warrant deeper TIJ investigation
Three items on today’s docket stand out as candidates for follow-up reporting:
- BiomX / DFSL (PHGE): A clinical-stage phage-therapy company acquiring a controlling interest in an Israeli defense engineering firm is a strategic pivot that demands scrutiny of valuation methodology, related-party disclosures, and segment reporting. TIJ will examine the subsequent 10-Q for segment-level transparency.
- Conagra Brands (CAG): CEO separation packages are a recurring focal point for shareholder advisory firms. TIJ will review the forthcoming DEF 14A for alignment between severance terms and long-term performance metrics.
- Paramount Skydance / WBD: The combined entity’s governance and editorial independence commitments — particularly how they are reflected in FCC filings and post-close Section 13(d) disclosures — will be followed as the transaction progresses.
Methodology and right-of-reply note
All factual claims in this briefing are sourced to public SEC filings, SEC press releases, or SEC litigation releases linked above. Hedging language is used throughout where cases remain pending or where the record is incomplete. Companies and individuals named in this digest may submit right-of-reply statements via the TIJ editorial contact, and substantive corrections will be appended within one business day. This column is published as part of TIJ’s daily Corporate Disclosure Watch.
Sources: SEC EDGAR (edgar/search); SEC Press Releases (newsroom/press-releases); SEC Litigation Releases (enforcement-litigation/litigation-releases).